Ralph Brandenberger,
Ph.D., to senior vice president, technical operations. Brandenberger joined the Nkarta team in 2018 and oversees the company s cell therapy manufacturing operations.
> Asklepios Biopharmaceutical tapped
Tracy Dowling as general counsel starting Jan. 25. Dowling will help manage and advise on corporate governance, business development transactions, license agreements, employment law and more. Most recently, Dowling served as associate general counsel at Spark Therapeutics.
> Precision oncology specialist OncoDNA signed on
Bernard Courtieu as CEO. Courtieu previously joined IntegraGen as CEO in 2007.
Eduardo Bravo,
OncoDNA s interim CEO since July 2020, will remain a consultant to the company s board.
> Abingdon Health named
Melanie Ross as chief financial officer, effective immediately. Ross will also serve on the company s board. Most recently, she was group finance director at GVO-B1; prior to that, Ross was chief financial office
Home / Top News / Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications
BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has expanded its senior management team with the appointments of Jayanthi Wolf, Ph.D., Senior Vice President of Regulatory Affairs and Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications.